12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

JNJ-39758979: Development discontinued

Johnson & Johnson disclosed that earlier this year it discontinued development of JNJ-39758979 after 2 cases of agranulocytosis, a severe drop in white blood cell count, were reported in a double-blind, placebo-controlled, Japanese Phase II...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >